# A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

> **NCT04063215** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hope Biosciences LLC** · enrollment: 24 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **BIOLOGICAL:** HB-adMSCs

## Key facts

- **NCT ID:** NCT04063215
- **Lead sponsor:** Hope Biosciences LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-01
- **Primary completion:** 2024-10-25
- **Final completion:** 2024-10-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04063215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04063215, "A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04063215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*